|
1
|
Warren AY and Harrison D: WHO/ISUP
classification, grading and pathological staging of renal cell
carcinoma: Standards and controversies. World J Urol. 36:1913–1926.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leibovich BC, Lohse CM, Crispen PL,
Boorjian SA, Thompson RH, Blute ML and Cheville JC: Histological
subtype is an independent predictor of outcome for patients with
renal cell carcinoma. J Urol. 183:1309–1315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lipworth L, Morgans AK, Edwards TL,
Barocas DA, Chang SS, Herrell SD, Penson DF, Resnick MJ, Smith JA
and Clark PE: Renal cell cancer histological subtype distribution
differs by race and sex. BJU Int. 117:260–265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI,
Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, et al: The
International metastatic renal cell carcinoma database consortium
model as a prognostic tool in patients with metastatic renal cell
carcinoma previously treated with first-line targeted therapy: A
population-based study. Lancet Oncol. 16:293–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campbell SC, Novick AC, Belldegrun A,
Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ,
Matin SF, et al: Guideline for management of the clinical T1 renal
mass. J Urol. 182:1271–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lindenberg L, Mena E, Choyke PL and
Bouchelouche K: PET imaging in renal cancer. Curr Opin Oncol.
31:216–221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herts BR and Baker ME: The current role of
percutaneous biopsy in the evaluation of renal masses. Semin Urol
Oncol. 13:254–261. 1995.PubMed/NCBI
|
|
8
|
Frank I, Blute ML, Cheville JC, Lohse CM,
Weaver AL and Zincke H: Solid renal tumors: an analysis of
pathological features related to tumor size. J Urol. 170:2217–2220.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Snyder ME, Bach A, Kattan MW, Raj GV,
Reuter VE and Russo P: Incidence of benign lesions for clinically
localized renal masses smaller than 7 cm in radiological diameter:
Influence of sex. J Urol. 176:2391–2396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baio R, Molisso G, Caruana C, Di Mauro U,
Intilla O, Pane U, D'Angelo C, Campitelli A, Pentimalli F and
Sanseverino R: ‘To be or not to be benign’ at partial nephrectomy
for presumed RCC renal masses: Single-center experience with 195
consecutive patients. Diseases. 11:272023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roussel E, Capitanio U, Kutikov A,
Oosterwijk E, Pedrosa I, Rowe SP and Gorin MA: Novel imaging
methods for renal mass characterization: A collaborative review.
Eur Urol. 81:476–488. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patel HD, Johnson MH, Pierorazio PM, Sozio
SM, Sharma R, Iyoha E, Bass EB and Allaf ME: Diagnostic accuracy
and risks of biopsy in the diagnosis of a renal mass suspicious for
localized renal cell carcinoma: Systematic review of the
literature. J Urol. 195:1340–1347. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Macklin PS, Sullivan ME, Tapping CR,
Cranston DW, Webster GM, Roberts ISD, Verrill CL and Browning L:
tumour seeding in the tract of percutaneous renal tumour biopsy: A
report on seven cases from a UK tertiary referral centre. Eur Urol.
75:861–867. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ronca R and Supuran CT: Carbonic anhydrase
IX: An atypical target for innovative therapies in cancer. Biochim
Biophys Acta Rev Cancer. 1879:1891202024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rademakers SE, Span PN, Kaanders JH, Sweep
FC, van der Kogel AJ and Bussink J: Molecular aspects of tumour
hypoxia. Mol Oncol. 2:41–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gatenby RA and Gawlinski ET: A
reaction-diffusion model of cancer invasion. Cancer Res.
56:5745–5753. 1996.PubMed/NCBI
|
|
17
|
Serrano-Oviedo L, Giménez-Bachs JM,
Nam-Cha SY, Cimas FJ, García-Cano J, Sánchez-Prieto R and
Salinas-Sánchez AS: Implication of VHL, ERK5, and HIF-1alpha in
clear cell renal cell carcinoma: Molecular basis. Urol Oncol.
35:114.e15–114.e22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grabmaier K, A de Weijert MC, Verhaegh GW,
Schalken JA and Oosterwijk E: Strict regulation of CAIX(G250/MN) by
HIF-1alpha in clear cell renal cell carcinoma. Oncogene.
23:5624–5631. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grabmaier K, Vissers JL, De Weijert MC,
Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, Noessner E,
Mulders PA, Merkx G, Figdor CG, et al: Molecular cloning and
immunogenicity of renal cell carcinoma-associated antigen G250. Int
J Cancer. 85:865–870. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ,
Pauwels EK, Jonas U, Zwartendijk J and Warnaar SO: Monoclonal
antibody G 250 recognizes a determinant present in renal-cell
carcinoma and absent from normal kidney. Int J Cancer. 38:489–494.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Battaglia M and Lucarelli G: The role of
renal surgery in the era of targeted therapy: The urologist's
perspective. Urologia. 82:137–138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Di Lorenzo G, De Placido S, Pagliuca M,
Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P,
Ascione I, et al: The evolving role of monoclonal antibodies in the
treatment of patients with advanced renal cell carcinoma: A
systematic review. Expert Opin Biol Ther. 16:1387–1401. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tamma R, Rutigliano M, Lucarelli G, Annese
T, Ruggieri S, Cascardi E, Napoli A, Battaglia M and Ribatti D:
Microvascular density, macrophages, and mast cells in human clear
cell renal carcinoma with and without bevacizumab treatment. Urol
Oncol. 37:355.e11–355.e19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ngwa W, Irabor OC, Schoenfeld JD, Hesser
J, Demaria S and Formenti SC: Using immunotherapy to boost the
abscopal effect. Nat Rev Cancer. 18:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Primac I, Tabury K, Tasdogan A, Baatout S
and Herrmann K: The molecular blueprint of targeted radionuclide
therapy. Nat Rev Clin Oncol. 22:869–894. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khanna R, Gape PMD, Grayson KC, Patel M
and Terry SYA: The power of precision: Unravelling the radiobiology
of targeted radionuclide therapy. Clin Oncol (R Coll Radiol).
48:1039232025. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stillebroer AB, Mulders PF, Boerman OC,
Oyen WJ and Oosterwijk E: Carbonic anhydrase IX in renal cell
carcinoma: Implications for prognosis, diagnosis, and therapy. Eur
Urol. 58:75–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muselaers S, Mulders P, Oosterwijk E, Oyen
W and Boerman O: Molecular imaging and carbonic anhydrase
IX-targeted radioimmunotherapy in clear cell renal cell carcinoma.
Immunotherapy. 5:489–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brouwers A, Verel I, Van Eerd J, Visser G,
Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G and
Boerman O: PET radioimmunoscintigraphy of renal cell cancer using
89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother
Radiopharm. 19:155–163. 2004.PubMed/NCBI
|
|
30
|
Cheal SM, Punzalan B, Doran MG, Evans MJ,
Osborne JR, Lewis JS, Zanzonico P and Larson SM: Pairwise
comparison of 89Zr- and 124I-labeled cG250 based on positron
emission tomography imaging and nonlinear immunokinetic modeling:
In vivo carbonic anhydrase IX receptor binding and internalization
in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl
Med Mol Imaging. 41:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stillebroer AB, Franssen GM, Mulders PF,
Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E and Boerman OC:
ImmunoPET imaging of renal cell carcinoma with (124)I- and
(89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer
Biother Radiopharm. 28:510–515. 2013.PubMed/NCBI
|
|
32
|
He C, Liu F, Tao J, Wang Z, Liu J, Liu S,
Xu X, Li L, Wang F, Yang X, et al: A CAIX dual-targeting
small-molecule probe for noninvasive imaging of ccRCC. Mol Pharm.
21:3383–3394. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang Y, Eng W, Shao C, Cheng G, Qiang C,
Peng W, Yang S and Liu S: Synthesis, preclinical characterizations
and imaging studies of [18F]AlF-Labeled NY104, a CAIX-Targeting
diagnostic agent. J Labelled Comp Radiopharm. 68:e41422025.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Minn I, Koo SM, Lee HS, Brummet M, Rowe
SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, et al:
[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear
cell renal cell carcinoma. Oncotarget. 7:56471–56479. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Krall N, Pretto F, Mattarella M, Müller C
and Neri D: A 99mTc-Labeled ligand of carbonic Anhydrase IX
selectively targets renal cell carcinoma in vivo. J Nucl Med.
57:943–949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Steffens MG, Oosterwijk E, Kranenborg MH,
Manders JM, Debruyne FM, Corstens FH and Boerman OC: In vivo and in
vitro characterizations of three 99mTc-labeled monoclonal antibody
G250 preparations. J Nucl Med. 40:829–836. 1999.PubMed/NCBI
|
|
37
|
Muselaers CH, Stillebroer AB, Rijpkema M,
Franssen GM, Oosterwijk E, Mulders PF, Oyen WJ and Boerman OC:
Optical imaging of renal cell carcinoma with anti-carbonic
anhydrase IX monoclonal antibody girentuximab. J Nucl Med.
55:1035–1040. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lawrentschuk N, Lee FT, Jones G,
Rigopoulos A, Mountain A, O'Keefe G, Papenfuss AT, Bolton DM, Davis
ID and Scott AM: Investigation of hypoxia and carbonic anhydrase IX
expression in a renal cell carcinoma xenograft model with oxygen
tension measurements and ¹24I-cG250 PET/CT. Urol Oncol.
29:411–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Muselaers CH, Rijpkema M, Bos DL,
Langenhuijsen JF, Oyen WJ, Mulders PF, Oosterwijk E and Boerman OC:
Radionuclide and fluorescence imaging of clear cell renal cell
carcinoma using dual labeled anti-carbonic anhydrase IX antibody
G250. J Urol. 194:532–538. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang X, Minn I, Rowe SP, Banerjee SR,
Gorin MA, Brummet M, Lee HS, Koo SM, Sysa-Shah P, Mease RC, et al:
Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif
inhibitor. Oncotarget. 6:33733–33742. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garousi J, Honarvar H, Andersson KG,
Mitran B, Orlova A, Buijs J, Löfblom J, Frejd FY and Tolmachev V:
Comparative evaluation of affibody molecules for radionuclide
imaging of in vivo expression of carbonic anhydrase IX. Mol Pharm.
13:3676–3687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Massière F, Wiedemann N, Borrego I, Hoehne
A, Osterkamp F, Paschke M, Zboralski D, Schumann A, Bredenbeck A,
Brichory F and Attinger A: Preclinical characterization of
DPI-4452: A 68Ga/177Lu theranostic ligand for carbonic anhydrase
IX. J Nucl Med. 65:761–767. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Filippi L, Urso L, D'Angelillo RM and
Evangelista L: Girentuximab imaging in renal cancer: Diamond in the
rough or just ZIRCON? Expert Rev Anticancer Ther. 25:91–95. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shuch B, Pantuck AJ, Bernhard JC, Morris
MA, Master V, Scott AM, van Praet C, Bailly C, Önal B, Aksoy T, et
al: [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal
cell carcinoma: A prospective, open-label, multicentre, phase 3
trial. Lancet Oncol. 25:1277–1287. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakaigawa N, Hasumi H, Utsunomiya D,
Yoshida K, Ishiwata Y, Oka T, Hayward C and Makiyama K: Evaluation
of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: A phase 1
clinical study in Japanese patients with renal cell carcinoma
(Zirdac-JP). Jpn J Clin Oncol. 54:873–879. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Merkx RIJ, Lobeek D, Konijnenberg M,
Jiménez-Franco LD, Kluge A, Oosterwijk E, Mulders PFA and Rijpkema
M: Phase I study to assess safety, biodistribution and radiation
dosimetry for 89Zr-girentuximab in patients with renal cell
carcinoma. Eur J Nucl Med Mol Imaging. 48:3277–3285. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Verhoeff SR, van Es SC, Boon E, van Helden
E, Angus L, Elias SG, Oosting SF, Aarntzen EH, Brouwers AH, Kwee
TC, et al: Lesion detection by [89Zr]Zr-DFO-girentuximab and
[18F]FDG-PET/CT in patients with newly diagnosed metastatic renal
cell carcinoma. Eur J Nucl Med Mol Imaging. 46:1931–1939. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hekman MCH, Rijpkema M, Aarntzen EH,
Mulder SF, Langenhuijsen JF, Oosterwijk E, Boerman OC, Oyen WJG and
Mulders PFA: Positron emission tomography/computed tomography with
89Zr-girentuximab can aid in diagnostic dilemmas of clear cell
renal cell carcinoma suspicion. Eur Urol. 74:257–260. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu W, Li X, Zheng G, Bai C, Ji Z, Zhang
H, Xing H, Zhang Y and Huo L: Preclinical and pilot clinical
evaluation of a small-molecule carbonic anhydrase IX targeting PET
tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol
Imaging. 50:3116–3125. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang L, Guo W, Ding H, Gao X, Xu Y, Wang
M, Yang X, Zhao Y, Wang W, Liu W, et al: Evaluation of the safety,
biodistribution, dosimetry of [18F]AlF-NYM005 and initial
experience in clear cell renal cell carcinoma: an interim analysis
of a prospective trial. Eur J Nucl Med Mol Imaging. 52:1354–1369.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Divgi CR, Uzzo RG, Gatsonis C, Bartz R,
Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P and
Russo P: Positron emission tomography/computed tomography
identification of clear cell renal cell carcinoma: Results from the
REDECT trial. J Clin Oncol. 31:187–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Povoski SP, Hall NC, Murrey DA Jr, Sharp
DS, Hitchcock CL, Mojzisik CM, Bahnson EE, Knopp MV, Martin EW Jr
and Bahnson RR: Multimodal imaging and detection strategy with 124
I-labeled chimeric monoclonal antibody cG250 for accurate
localization and confirmation of extent of disease during
laparoscopic and open surgical resection of clear cell renal cell
carcinoma. Surg Innov. 20:59–69. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Divgi CR, Pandit-Taskar N, Jungbluth AA,
Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, et
al: Preoperative characterisation of clear-cell renal carcinoma
using iodine-124-labelled antibody chimeric G250 (124I-cG250) and
PET in patients with renal masses: A phase I trial. Lancet Oncol.
8:304–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brouwers AH, Buijs WC, Oosterwijk E,
Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF and Oyen
WJ: Targeting of metastatic renal cell carcinoma with the chimeric
monoclonal antibody G250 labeled with (131)I or (111)In: An
intrapatient comparison. Clin Cancer Res. 9:3953S–3960S.
2003.PubMed/NCBI
|
|
55
|
Kulterer OC, Pfaff S, Wadsak W, Garstka N,
Remzi M, Vraka C, Nics L, Mitterhauser M, Bootz F, Cazzamalli S, et
al: A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging
of primary and metastatic lesions in renal cell carcinoma patients.
J Nucl Med. 62:360–365. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
van Oostenbrugge TJ, Langenhuijsen JF,
Oosterwijk E, Boerman OC, Jenniskens SF, Oyen WJG, Fütterer JJ and
Mulders PFA: Follow-up imaging after cryoablation of clear cell
renal cell carcinoma is feasible using single photon emission
computed tomography with 111In-girentuximab. Eur J Nucl Med Mol
Imaging. 47:1864–1870. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hekman MC, Rijpkema M, Muselaers CH,
Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, Oyen WJ,
Langenhuijsen JF and Mulders PF: Tumor-targeted dual-modality
imaging to improve intraoperative visualization of clear cell renal
cell carcinoma: A first in man study. Theranostics. 8:2161–2170.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Muselaers CH, Boerman OC, Oosterwijk E,
Langenhuijsen JF, Oyen WJ and Mulders PF: Indium-111-labeled
girentuximab immunoSPECT as a diagnostic tool in clear cell renal
cell carcinoma. Eur Urol. 63:1101–1106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Morgan KA, Wichmann CW, Osellame LD, Cao
Z, Guo N, Scott AM and Donnelly PS: Tumor targeted alpha particle
therapy with an actinium-225 labelled antibody for carbonic
anhydrase IX. Chem Sci. 15:3372–3381. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Merkx RIJ, Rijpkema M, Franssen GM, Kip A,
Smeets B, Morgenstern A, Bruchertseifer F, Yan E, Wheatcroft MP,
Oosterwijk E, et al: Carbonic anhydrase IX-targeted α-radionuclide
therapy with 225Ac inhibits tumor growth in a renal cell carcinoma
model. Pharmaceuticals (Basel). 15:5702022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Muselaers CH, Oosterwijk E, Bos DL, Oyen
WJ, Mulders PF and Boerman OC: Optimizing lutetium
177-anti-carbonic anhydrase IX radioimmunotherapy in an
intraperitoneal clear cell renal cell carcinoma xenograft model.
Mol Imaging. 13:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Muselaers CH, Boers-Sonderen MJ, van
Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF,
van Herpen CM, Langenhuijsen JF, Oosterwijk E, et al: Phase 2 study
of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal
antibody girentuximab in patients with advanced renal cell
carcinoma. Eur Urol. 69:767–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Stillebroer AB, Boerman OC, Desar IM,
Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM,
Oosterwijk E, Oyen WJ and Mulders PF: Phase 1 radioimmunotherapy
study with lutetium 177-labeled anti-carbonic anhydrase IX
monoclonal antibody girentuximab in patients with advanced renal
cell carcinoma. Eur Urol. 64:478–485. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Stillebroer AB, Zegers CM, Boerman OC,
Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP and Oyen WJ:
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell
carcinoma patients: Correlation with myelotoxicity and
pretherapeutic absorbed dose predictions based on 111In-cG250
imaging. J Nucl Med. 53:82–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Brouwers AH, Buijs WC, Mulders PF, de
Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC,
Corstens FH and Oyen WJ: Radioimmunotherapy with [131I]cG250 in
patients with metastasized renal cell cancer: Dosimetric analysis
and immunologic response. Clin Cancer Res. 11((19 Pt 2)):
7178s–7186s. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Divgi CR, Bander NH, Scott AM, O'Donoghue
JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams
JM, et al: Phase I/II radioimmunotherapy trial with
iodine-131-labeled monoclonal antibody G250 in metastatic renal
cell carcinoma. Clin Cancer Res. 4:2729–2739. 1998.PubMed/NCBI
|
|
67
|
Parihar AS, Chopra S and Prasad V:
Nephrotoxicity after radionuclide therapies. Transl Oncol.
15:1012952022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vilangattil MM, Swaidan A, Godinez J,
Taddio MF, Czernin J, Mona CE and Carlucci G: Hematological
toxicity of [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 in RM1-PGLS
syngeneic mouse model. EJNMMI Radiopharm Chem. 10:122025.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Uehara T, Koike M, Nakata H, Hanaoka H,
Iida Y, Hashimoto K, Akizawa H, Endo K and Arano Y: Design,
synthesis, and evaluation of [188Re]organorhenium-labeled antibody
fragments with renal enzyme-cleavable linkage for low renal
radioactivity levels. Bioconjug Chem. 18:190–198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kamaldeep Thapa P, Wanage G, Tervankar S,
Kaisar S, Ranade R, Basu S, Das T and Banerjee S: Prospective
evaluation of organ-specific dose and lesional doses following
therapeutic [177Lu]Lu-EDTMP administration in patients with
multiple skeletal metastases and its correlation with clinical
hematological toxicity. Nucl Med Commun. 42:1076–1084. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bodei L, Cremonesi M, Ferrari M, Pacifici
M, Grana CM, Bartolomei M, Baio SM, Sansovini M and Paganelli G:
Long-term evaluation of renal toxicity after peptide receptor
radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role
of associated risk factors. Eur J Nucl Med Mol Imaging.
35:1847–1856. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kesavan M, Claringbold PG and Turner JH:
Hematological toxicity of combined 177Lu-octreotate radiopeptide
chemotherapy of gastroenteropancreatic neuroendocrine tumors in
long-term follow-up. Neuroendocrinology. 99:108–117. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Baum RP, Kulkarni HR and Carreras C:
Peptides and receptors in image-guided therapy: Theranostics for
neuroendocrine neoplasms. Semin Nucl Med. 42:190–207. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Waldherr C, Pless M, Maecke HR, Schumacher
T, Crazzolara A, Nitzsche EU, Haldemann A and Mueller-Brand J:
Tumor response and clinical benefit in neuroendocrine tumors after
7.4 GBq (90)Y-DOTATOC. J Nucl Med. 43:610–616. 2002.PubMed/NCBI
|
|
75
|
Ezziddin S, Sabet A, Heinemann F,
Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, Höller T, Willinek W, Boy
C and Biersack HJ: Response and long-term control of bone
metastases after peptide receptor radionuclide therapy with
(177)Lu-octreotate. J Nucl Med. 52:1197–1203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bernard BF, Krenning EP, Breeman WA,
Rolleman EJ, Bakker WH, Visser TJ, Mäcke H and de Jong M: D-lysine
reduction of indium-111 octreotide and yttrium-90 octreotide renal
uptake. J Nucl Med. 38:1929–1933. 1997.PubMed/NCBI
|
|
77
|
Emmett L, Willowson K, Violet J, Shin J,
Blanksby A and Lee J: Lutetium 177 PSMA radionuclide therapy for
men with prostate cancer: A review of the current literature and
discussion of practical aspects of therapy. J Med Radiat Sci.
64:52–60. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
An S, Wang L, Xie F, Jiang D, Huang G, Liu
J, Ma X and Wei W: Pathway to approval of innovative
radiopharmaceuticals in China. J Nucl Med. 65 (Suppl 1):72S–76S.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tran HH, Yamaguchi A and Manning HC:
Radiotheranostic landscape: A review of clinical and preclinical
development. Eur J Nucl Med Mol Imaging. 52:2685–2709. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Herscovitch P: Regulatory agencies and
PET/CT imaging in the clinic. Curr Cardiol Rep. 24:1361–1371. 2022.
View Article : Google Scholar : PubMed/NCBI
|
